Journal Information
Vol. 28. Issue. 5.October 2008
Pages 475-573
Vol. 28. Issue. 5.October 2008
Pages 475-573
DOI:
Full text access
Recovery of total innmunoglobulin and immunoglobulin subclasses in nephrotic syndrome: deflazacort vs methylprednisone
Recuperación de la inmnoglobulina total y sus subclases en el síndrome nefrótico: deflazacort vs metilprednisona.
Visits
7218
Miguel Lierna, StellaMaris Diegueza, Carlos Canepaa
a Servicio de Nefrologia, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Buenos Aires, Argentina
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
La hipogamaglobulinemia en el síndrome nefrótico (SN) es una alteración atribuible a un aumento de su catabolismo y a la perdida urinaria de las inmunoglobulinas (1,2)
To the editor: Hypogammaglobulinemia in nephrotic syndrome (NS) is a condition attributable to increased catabolism and urinary loss of immunoglobulins.1,2
Full Text

To the editor: Hypogammaglobulinemia in nephrotic syndrome (NS) is a condition attributable to increased catabolism and urinary loss of immunoglobulins.1,2



Patients with NS have an increased risk of infection, primarily caused by capsulated germs (pneumococci, Hemophilus influenzae).3,4 There is evidence suggesting that IgG2 are antibodies protecting against pneumococci.



Our purpose was to study recovery of the different immunoglobulin subclasses in patients with NS treated with methylprednisone and deflazacort during remission and relapse.



PATIENTS AND METHODS



Eleven patients with a mean age of 48 months (range, 16-52 months) were studied. An interventional, single blind, clinical study, randomized for treatment start and with treatment crossover after the first relapse, was designed.



Methylprednisone (MPD) was given at 48 mg/m2/day for 6 weeks, followed by 2/3 of the dose every other day for

the next 6 weeks.



The equivalent dose of deflazacort (DFZ) was 72 mg/m2/day (maximum 90 mg/day), with the same therapeutic scheme.



Blood samples were taken at relapse and 40 days after remission was achieved to measure total IgG and its subclasses by the radial immunodiffusion method.



RESULTS



Mean times on remission were 7.8 ± 0.36 days with MPD and 8.3 ± 0.22 days with DFZ.



Mean times to relapse were 85 ± 3.8 days with MPD and 102 ± 4.19 days with DFZ.



Both total IgG and IgG1 similarly recovered with both corticosteroids, but IgG2 and IgG3 only significantly increased with DFZ. Percent recovery of IgG and its subclasses was asymmetric during remission.



IgG1  showed  the  greatest  recovery, while  IgG2  reached  50%  of  normal value. The  same  imbalance was  found with both treatments.



While this was not considered as an objective, it may be stated that the incidence rate of infection by capsulated germs was not significant with both corticosteroids (p0.12) and that less adverse effects occurred when DFZ was used (hypertrichosis, Cushingoid appearance, ocular hypertension, hyperglycemia).



CONCLUSIONS



We found an imbalance in recovery of IgG subclasses during remission of NS treated with both corticosteroids, but a better recovery of such levels was achieved with DFZ.

Bibliography
[1]
Longsworth IG, Mac Innes D.A. An electrophoretic study of nephrotic sera and urine. J.Exp>Med 1998; 71:77-82
[2]
2.Vivi-Anne Oxelius IgG Subclass levels in infancy and childhood Act Pediatr Scand 1979; 68:23-27
[3]
Lowy Y, Brezin C, Neauport-Sautes C, Theze J, Fridman WH. Isotype regulation of antibody production :T-cell hybrids can be selectively induced to produce IgG1 and IgG2 subclass-specific suppressive immunoglobulin-binding factors Proc Natl Acad Sci USA 2003; Apr;80(8):2323-7 [Pubmed]
[4]
4 Lowy Y, Theze J, Regulation of IgG1 and IgG2 subclass expression by adjuvant-activated splenic suppresser T-cell Cell.immunol 1999;Apr 1;91(2):467-76
Download PDF
Idiomas
Nefrología (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?